Evaluation of barriers to therapeutic drug monitoring in the management of hidradenitis suppurativa

Y Hilerowicz^{1

2}, N J Levin^{1

3}, J Parmar⁴, A Halavi^{5

6}, H Lev-Tov¹

Affiliations

¹ Dr Phillip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, FL, USA.
² Department of Dermatology, Tel Aviv University, Tel Aviv, Israel.
³ Florida Atlantic University Charles E. Schmidt College of Medicine, Boca Raton, FL, USA.
⁴ Department of Clinical and Administrative Sciences, Larkin University College of Pharmacy, Miami, FL, USA.
⁵ Department of Dermatology, Mayo Clinic, Rochester, MN, USA.
⁶ Division of Dermatology, Department of Medicine, Women's College Hospital, Toronto, ON, Canada.

Y Hilerowicz et al. Clin Exp Dermatol. 2021 Jul.

. 2021 Jul;46(5):936-938.

doi: 10.1111/ced.14602. Epub 2021 Mar 23.

Y Hilerowicz^{1

2}, N J Levin^{1

3}, J Parmar⁴, A Halavi^{5

6}, H Lev-Tov¹

¹ Dr Phillip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, FL, USA.
² Department of Dermatology, Tel Aviv University, Tel Aviv, Israel.
³ Florida Atlantic University Charles E. Schmidt College of Medicine, Boca Raton, FL, USA.
⁴ Department of Clinical and Administrative Sciences, Larkin University College of Pharmacy, Miami, FL, USA.
⁵ Department of Dermatology, Mayo Clinic, Rochester, MN, USA.
⁶ Division of Dermatology, Department of Medicine, Women's College Hospital, Toronto, ON, Canada.

No abstract available

References

1. Zouboulis CC, Okun MM, Prens EP et al. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol 2019; 80: 60-9.e62.
1. Nader A, Beck D, Noertersheuser P et al. Population pharmacokinetics and immunogenicity of adalimumab in adult patients with moderate-to-severe hidradenitis suppurativa. Clin Pharmacokinet 2017; 56: 1091-102.
1. Reich K, Jackson K, Ball S et al. Ixekizumab pharmacokinetics, anti-drug antibodies, and efficacy through 60 weeks of treatment of moderate to severe plaque psoriasis. J Invest Dermatol 2018; 138: 2168-73.
1. Liau MM, Oon HH. Therapeutic drug monitoring of biologics in psoriasis. Biologics 2019; 13: 127-32.
1. Vande Casteele N, Herfarth H, Katz J et al. American Gastroenterological Association Institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases. Gastroenterology 2017; 153: 835-57.e6.